Table 3 Changes following subcutaneous infusion of apomorphine in patients with Parkinson’s disease (n = 51).

Time period	Baseline	Month 6	p^a	Month 12	p^b	p^c
Measure	Mean ± SD (range)	Mean ± SD (range)	p^a	Mean ± SD (range)	p^b	p^c
Dose of medication
LEDD	823.73 ± 267.17 (400–1800)	574.51 ± 169.52 (200–1000)	< 0.001	407.84 ± 132.43 (200–800)	< 0.001	< 0.001
Apomorphine	–	24.67 ± 4.19 (18–36)	–	36.00 ± 6.79 (24–60)	–	< 0.001
UPDRS
Part 2^d	30.18 ± 1.85 (27–33)	23.41 ± 2.30 (19–27)	< 0.001	–
Part 3	46.78 ± 4.21 (39–57)	34.96 ± 2.03 (30–39)	< 0.001	34.43 ± 0.86 (33–36)	< 0.001	n.s.
Part 4	17.78 ± 2.33 (13–22)	14.02 ± 1.42 (12–18)	< 0.001	11.98 ± 1.52 (9–15)	< 0.001	< 0.001
NMSS total^e	128.06 ± 18.33 (87–161)	95.51 ± 100.0 (68–118)	< 0.001	78.00 ± 21.32 (46–124)	< 0.001	< 0.001
PDQ-8 Summary index	59.56 ± 7.45 (43.75–75.0)	42.50 ± 5.54 (37.5–53.13)	< 0.001	43.75 ± 5.56 (37.5–53.13)	< 0.001	n.s.
HADS-Depression	12.22 ± 2.06 (8–18)	10.51 ± 1.43 (6–14)	< 0.001	10.51 ± 1.43 (6–14)	< 0.001	n.s.
HADS-Anxiety	13.02 ± 7.75 (9–18)	10.31 ± 1.53 (6–14)	< 0.001	10.51 ± 1.43 (6–14)	< 0.001	n.s.
MOCA	24.55 ± 2.77 (20–30)	24.55 ± 2.77 (20–30)	n.s.	24.59 ± 2.66 (20–30)	n.s.	n.s.
PFS-16	11.16 ± 3.66 (0–16)	9.33 ± 2.78 (0–12)	< 0.001	9.82 ± 3.03 (0–16)	< 0.001	n.s.
PDSS	63.55 ± 18.07 (20–90)	66.18 ± 12.63 (30–90)	n.s.	66.18 ± 12.36 (30–90)	n.s.	n.s.
KPPS	40.59 ± 8.56 (21–67)	33.69 ± 9.10 (20–60)	< 0.001	33.29 ± 9.23 (20–60)	< 0.001	n.s.

^aWilcoxon test for baseline vs month 6 scores; ^bWilcoxon test for baseline vs month 12 scores; ^cWilcoxon test for month 6 vs month 12 scores; ^dSD Standard deviation, LEDD Levodopa equivalent daily dose, UPDRS Unified Parkinson’s disease rating scale, NMSS non motor symptoms scale, PDQ-8 8-item Parkinson's disease questionnaire, HADS hospital anxiety and depression scale, MOCA Montreal cognitive assessment, PFS-16 Parkinson’s disease fatigue scale, PDSS Parkinson’s disease sleep scale, KPPS King’s PD Pain Scale.

Search